Table 1.
Patient characteristics
| Characteristic | Value (n=31) |
|---|---|
| Age, yr | 66.2±12.1 |
| Sex, female | 18 (58.1) |
| Diabetes | 18 (58.1) |
| Hemoglobin A1c, % (n=17) | 7.2±1.4 |
| Duration of diabetes, mo (n=16) | 17.0±10.8 |
| Hypertension | 27 (87.1) |
| History of nephrolithiasis | 13 (42.0) |
| Alcohol use | 10 (32.3) |
| Smoking/tobacco use | 10 (32.3) |
| CKD, yes (n=30) a | 24 (77.4) |
| Stage; 2/3/4/5 (n=23) | 1/16/4/2 |
| Serum creatinine at baseline (mg/dl) (n=30) | 1.8±1.3 |
| Serum creatinine at presentation (mg/dl) (n=29) | 7.6±3.4 |
| Serum creatinine at biopsy (mg/dl) (n=30) | 5.2±1.7 |
| Baseline eGFR (ml/min per 1.73 m2) (n=30) | 48.0±29.3 |
| Serum oxalate (mcmol/L) (n=9) | 19.0±15.4 |
| 24-h urine oxalate (mg) (n=7) | 47.1±8.9 |
| Vitamin C, yes | 8 (25.8) |
| Daily vitamin C amount; 500/1000 mg/other (iv or multivitamin form) (n=8) | 1/5/2 |
| Diuretic use (n=30)a | 13 (43.3) |
| RAAS inhibitor use | 15 (48.4) |
| Antibiotic use (n=28)a | 10 (32.3) |
| Polyethylene glycol-3350 use (within 1 yr) | 19 (61.3) |
| BMI (kg/m2) | 30.0±9.2 |
| Follow-up length, mo (n=26) | 26.8±21.3 (13–40) |
| Time until death event, mo (n=12)b | 19.8±18.9 (6–29) |
Mean±SD, n (%). BMI, body mass index; RAAS, renin–angiotensin aldosterone system.
a
Percentage was calculated from numerator of n=31.
b
Time until death event among 12 patients who were deceased at entire follow-up.